$177.12
-6.67(-3.63%)
Mkt Cap $26.0B
$113.38
$201.18
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Product (39.7%), MS Product Revenues (12%), Revenues From Anti CD20Therapeutic Programs (7.3%).
8-K
Biogen Inc. announced a definitive agreement to acquire Apellis Pharmaceuticals for $41 per share in cash plus a CVR, adding SYFOVRE and EMPAVELI to enhance its immunology and nephrology growth portfolio.$26.0B
Market Cap
$9.8B
Revenue
$1.3B
Net Income
Employees7,605
Fundamentals
How The Business Makes Money
Revenue by Segment
Product39.7%($86.3B)
MS Product Revenues12%($26.1B)
Revenues From Anti CD20Therapeutic Programs7.3%($15.9B)
Rare Disease Product Revenue5.5%($11.9B)
Tysabri Product4.8%($10.5B)
SPINRAZA4.5%($9.7B)
Fumarate4.2%($9.2B)
Contract Manufacturing Royalty And Other Revenue3.2%($6.9B)
Interferon2.8%($6.0B)
TECFIDERA2.4%($5.3B)
Biosimilars2.1%($4.6B)
AVONEX2%($4.4B)
Royalty Attributed To OCREVUS1.9%($4.0B)
VUMERITY1.8%($3.9B)
BENEPALI1.3%($2.7B)
Contract Manufacturing And Other Revenue1%($2.1B)
SKYCLARYS0.9%($1.9B)
PLEGRIDY0.7%($1.6B)
IMRALDI0.6%($1.3B)
Other0.3%($583M)
ZURZUVAE0.2%($538M)
FLIXABI0.2%($386M)
FAMPYRA0.2%($327M)
QALSODY0.1%($250M)
Alzheimers Collaboration0.1%($238M)
BYOOVIZ0.1%($201M)
Royalty0.1%($165M)
FUMADERM And ADUHELM0%($45M)
TOFIDENCE0%($4M)
Revenue by Geography
US49.6%($50.4B)
Non Us37.9%($38.5B)
Europe Excluding Germany6.1%($6.2B)
DE2.6%($2.7B)
Asia2.2%($2.2B)
Segment Geographical Groups Of Countries Group Other1.6%($1.6B)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000875045
ISINUS09062X1037
CUSIP09062X103
Phone617 679 2000
Address225 Binney Street, Cambridge, MA, 02142, US
SEC EDGAR